May 28, 2019
Bob Anderson PhD, Chief Scientific Officer, ImmusanT is an internationally recognized leader in celiac disease research. He talks about the underlying causes of celiac, who is most likely to have an acquired immune response to fragments of the gluten protein, educating doctors about the need to test for celiac, the Phase 2 clinical trial results for Nexvax2 a therapeutic vaccine to treat celiac, and how the ImmusanT platform technology is allowing development of therapeutic vaccines for diabetes and other autoimmune conditions.
#diabetes #autoimmunediseases #tcell
#glutenpeptides #peptides #gluten